Concert Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that it will be presenting at the 28th Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, California. Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present an overview of the Company on Monday, January 11, 2010 at 9:00 a.m. (PT).
Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. In 2009, Concert entered into a potential $1 billion strategic alliance with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.
Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert Pharmaceuticals, Inc.